CSL689

BIOLOGICAL2 trials

Sponsors

CSL Behring

Conditions

Congenital Coagulation Factor VII DeficiencyHemophilia A With InhibitorsHemophilia B With Inhibitors

Phase 1

Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency

CompletedNCT02470871

CSL BehringCongenital Coagulation Factor VII Deficiency

Start: 2015-07-31End: 2016-10-31Updated: 2017-04-26

Phase 2

Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

TerminatedNCT02484638

CSL BehringHemophilia A With Inhibitors, Hemophilia B With Inhibitors

Start: 2015-07-23End: 2018-03-28Updated: 2019-08-28

Related Papers

Pharmacokinetics and pharmacodynamics of a recombinant fusion protein linking activated coagulation factor VII with human albumin (rVIIa-FP) in patients with congenital FVII deficiency

Hematology2019-12-189 citations